| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | ACUCELA INC. | 600 UNIVERSITY ST | SEATTLE | WA | 98101-4174 | KING | USA | R01FD006849 | A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019) | 000 | 3 | FDA | 4/29/2024 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $545,000 ) |
| | 2022 | 2022 | ACUCELA INC. | 600 UNIVERSITY ST STE 2900 | SEATTLE | WA | 98101-4174 | KING | USA | R01FD006849 | A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019) | 000 | 3 | FDA | 5/20/2022 | $545,000 |
|
| Issue Date FY: 2021 ( Subtotal = $545,000 ) |
| | 2021 | 2021 | ACUCELA INC. | 600 UNIVERSITY ST STE 2900 | SEATTLE | WA | 98101-4174 | KING | USA | R01FD006849 | A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019) | 000 | 2 | FDA | 6/30/2021 | $545,000 |
|
| Issue Date FY: 2020 ( Subtotal = $543,917 ) |
| | 2020 | 2020 | ACUCELA INC. | 818 STEWART ST STE 1110 | SEATTLE | WA | 98101-1479 | KING | USA | R01FD006849 | A Phase 3 Study of Emixustat Hydrochloride for Stargardt Disease IND 101,084 (02/11/2019) | 000 | 1 | FDA | 8/20/2020 | $543,917 |
|
| Issue Date FY: 2010 ( Subtotal = $0 ) |
| | 2010 | 2007 | ACUCELA INC | 454 NORTH 34TH STREET | SEATTLE | WA | 98103 | KING | USA | R43EY018266 | IDENTIFYING CYTOPROTECTANTS FOR PHOTORECEPTORS AND RPE CELLS TO TREAT DRY AMD | 000 | 1 | NIH | 12/10/2009 | $0 |
|
| Issue Date FY: 2007 ( Subtotal = $199,295 ) |
| | 2007 | 2007 | ACUCELA INC | 454 NORTH 34TH STREET | SEATTLE | WA | 98103 | KING | USA | R43EY018266 | IDENTIFYING CYTOPROTECTANTS FOR PHOTORECEPTORS AND RPE CELLS TO TREAT DRY AMD | 000 | 1 | NIH | 9/30/2007 | $99,295 |
| | 2007 | 2007 | ACUCELA INC | 454 NORTH 34TH STREET | SEATTLE | WA | 98103 | KING | USA | R43ES015667 | IN VITRO ASSAY TO ASSESS CHEMICAL TOXICITY IN RETINAL PRIMARY CELL CULTURES | 000 | 1 | NIH | 9/12/2007 | $100,000 |
|
|
